Aldose reductase (AR) has been a long-standing target for treating diabetic complications, but its structural similarity to related enzymes has made selective inhibition difficult. Off-target binding ...
Researchers from ICTER have developed a fragment-based drug discovery method combined with microcrystal electron diffraction to design enzyme inhibitors at atomic resolution. The approach aims to ...
1d
No more guesswork in drug design—atomic-resolution method exposes what trial and error keep missing
Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...
The ICMR-National Institute of Nutrition has developed a poly-herbal extract that goes beyond blood sugar control to target complications linked to diabetes and obesity, including kidney damage, ...
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: ...
Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 ...
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare ...
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Thursday, means it has indeed aligned with the FDA on govorestat’s development. Applied Therapeutics has ...
What if the sugar we consume, or even the sugar our own bodies produce, could increase the risk of cancer? That’s the question driving groundbreaking research by Hyeyoung Nam, Ph.D., instructor in the ...
The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results